The latest financial statement is for the quarter ending 2025-06-30.
| Cash Flow | 2025-06-30 |
|---|---|
| Restricted cash | 0 |
| Cash and cash equivalents, at carrying value, total | 119,437 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | 119,437 |
Enliven Therapeutics, Inc. (IMRA)
Enliven Therapeutics, Inc. (IMRA)